ArticleOncotarget2016
The 3'UTR signature defines a highly metastatic subgroup of triple-negative breast cancer.
Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Engineering overexpressing SYNGR1 inhibited the progression of GBM cells by suppressing the intracellular FGF1-mediated LDs accumulation and cytoskeleton remodeling.Journal of neuro-oncology · 2025Article
- Omics Technologies Improving Breast Cancer Research and Diagnostics.International journal of molecular sciences · 2023Review
- Article
- Antisense Oligonucleotide-Based Therapeutic against Menin for Triple-Negative Breast Cancer Treatment.Biomedicines · 2021Article
- The Detection and Bioinformatic Analysis of Alternative 3International journal of molecular sciences · 2021Review
- Single cell RNA sequencing for breast cancer: present and future.Cell death discovery · 2021Review
- Alternative polyadenylation: methods, mechanism, function, and role in cancer.Journal of experimental & clinical cancer research : CR · 2021Review
- Alternative polyadenylation of mRNA and its role in cancer.Genes & diseases · 2021Review
- Systemic Analysis of the Prognosis-Associated Alternative Polyadenylation Events in Breast Cancer.Frontiers in genetics · 2020Article
- Dissecting the heterogeneity of the alternative polyadenylation profiles in triple-negative breast cancers.Theranostics · 2020Observational
- hnRNPC regulates cancer-specific alternative cleavage and polyadenylation profiles.Nucleic acids research · 2019Article
- Integrative 3' Untranslated Region-Based Model to Identify Patients with Low Risk of Axillary Lymph Node Metastasis in Operable Triple-Negative Breast Cancer.The oncologist · 2019Article
- Alternative polyadenylation of single cells delineates cell types and serves as a prognostic marker in early stage breast cancer.PloS one · 2019Article
- Detection of Differentially Expressed Cleavage Site Intervals Within 3' Untranslated Regions Using CSI-UTR Reveals Regulated Interaction Motifs.Frontiers in genetics · 2019Article
- The structural basis of CstF-77 modulation of cleavage and polyadenylation through stimulation of CstF-64 activity.Nucleic acids research · 2018Article
- TC3A: The Cancer 3' UTR Atlas.Nucleic acids research · 2018Article
- Article
- Framework for reanalysis of publicly available Affymetrix® GeneChip® data sets based on functional regions of interest.BMC genomics · 2017Article
- Article
- Overlooked FANCD2 variant encodes a promising, portent tumor suppressor, and alternative polyadenylation contributes to its expression.Oncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triple-negative breast cancer (TNBC) is a highly heterogeneous disease with an aggressive clinical course. Prognostic models are needed to chart potential patient outcomes. To address this, we used alternative 3'UTR patterns to improve postoperative risk stratification. We collected 327 publicly available microarrays and generated the 3'UTR landscape based on expression ratios of alternative 3'UTR. After initial feature filtering, we built a 17-3'UTR-based classifier using an elastic net model. Time-dependent ROC comparisons and Kaplan-Meier analyses confirmed an outstanding discriminating power of our prognostic model for TNBC patients. In the training cohort, 5-year event-free survival (EFS) was 78.6% (95% CI 71.2-86.0) for the low-risk group, and 16.3% (95% CI 2.3-30.4) for the high-risk group (log-rank p<0.0001; hazard ratio [HR] 8.29, 95% CI 4.78-14.4), In the validation set, 5-year EFS was 75.6% (95% CI 68.0-83.2) for the low-risk group, and 33.2% (95% CI 17.1-49.3) for the high-risk group (log-rank p<0.0001; HR 3.17, 95% CI 1.66-5.42). In conclusion, the 17-3'UTR-based classifier provides a superior prognostic performance for estimating disease recurrence and metastasis in TNBC patients and it may permit personalized management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.